Jessica Aldrich

Title: Innovations in Cancer Treatment by Jessica Aldrich

Introduction

Jessica Aldrich is a prominent inventor based in Phoenix, AZ, who has made significant contributions to the field of cancer research. With a focus on targeted therapies, she has developed innovative methods for detecting and treating cancers associated with NRG1 fusion events. Her work has the potential to improve patient outcomes and advance the understanding of cancer treatment.

Latest Patents

Jessica Aldrich holds two patents related to targeted therapies for cancer. These patents provide compositions and methods for detecting cancers containing an NRG1 fusion event and treating patients with therapeutic agents specifically targeted to this fusion. The exemplary compositions include therapeutic agents that inhibit Epidermal Growth Factor Receptor and/or ERBB2, such as cetuximab, panitumumab, Sym004, MM-151, mAb 806, mAb 528, MEHD794A, gefitinib, erlotinib, lapatinib, afatinib, PD153035, AG1478, trastuzumab, and pertuzumab. In some embodiments, the therapeutic agent may be a combination of trastuzumab and pertuzumab.

Career Highlights

Throughout her career, Jessica has worked with esteemed organizations such as the Translational Genomics Research Institute and the Mayo Foundation for Medical Education and Research. Her experience in these institutions has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of Jessica's notable coworkers include John Carpten and David Craig, who have played significant roles in her research endeavors. Their collaboration has further enhanced the impact of her work in cancer treatment.

Conclusion

Jessica Aldrich's innovative approaches to cancer treatment through targeted therapies highlight her dedication to improving patient care. Her patents and collaborations reflect her commitment to advancing the field of oncology.